May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Interest of Intravitreal Bevacizumab Injection for Diabetic Macular Edema
Author Affiliations & Notes
  • O. Semoun
    Hopital des Quinze Vingts, Paris, France
  • Y. Salhi
    Hopital des Quinze Vingts, Paris, France
  • R. Adam
    Hopital des Quinze Vingts, Paris, France
  • I. Zundane
    Hopital des Quinze Vingts, Paris, France
  • T. Rodallec
    Hopital des Quinze Vingts, Paris, France
  • F.-X. Broussaud
    Hopital des Quinze Vingts, Paris, France
  • B. Dufay-Dupar
    Hopital des Quinze Vingts, Paris, France
  • O. Laplace
    Hopital des Quinze Vingts, Paris, France
  • J.-P. Nordmann
    Hopital des Quinze Vingts, Paris, France
  • Footnotes
    Commercial Relationships  O. Semoun, None; Y. Salhi, None; R. Adam, None; I. Zundane, None; T. Rodallec, None; F. Broussaud, None; B. Dufay-Dupar, None; O. Laplace, None; J. Nordmann, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 3499. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      O. Semoun, Y. Salhi, R. Adam, I. Zundane, T. Rodallec, F.-X. Broussaud, B. Dufay-Dupar, O. Laplace, J.-P. Nordmann; Interest of Intravitreal Bevacizumab Injection for Diabetic Macular Edema. Invest. Ophthalmol. Vis. Sci. 2008;49(13):3499. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : to evaluate action of Bevacizumab on diabetic macular edema

Methods: : we propose to evaluate Bevacizumab intravitreal action in 30 patients with PPR and diabetic macular edema and to folow macular edema evolution at one month and 6 months. Five patients had also simultaneous subtenon dexamethason injection. This small subgroup had triamcinolone intravitreal and subtenon injections in the past. Clinical examination with ETDRS, fluorescein angiography and optic coherence tomography (OCT) were done before injection and at one month. At 6 months, ETDRS and OCT control were realised.

Results: : on 30 patients, 21 (70%) presented some regression of macular edema. In 30% cases no effect was observed on macular edema. One patient presented severe tractional retinal detachment after injection. No retinal ischemia or atrophy and no intraocular inflammation was noticed because of injection. 30% of patients had undergone a triamcinolone intravitreal injection previously and had persistant macular edema before decision to inject bevacizumab intravitreally. This group often showed just diminishment of edema dome by one third at least (90%),but complete resolution of edema was rare (10%).Better resolution of diabetic edema showed the group of intravitreal bevacizumab injection combined with subtenon dexamethason injection where reduction of the edema was higher by 10% than single bevacizumab injection.

Conclusions: : Intravitreal injection of bevacizumab is an alternative therapeutic solution of resistant diabetic macular edema. It must be used with caution in diabetic edema after PPR and risk must be evaluated on a biger trial.

Keywords: retina • diabetes 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×